Manchado-Perero, Sofía; Rodríguez-Lorente, Ana; García-Pérez, Alba-María; García, Guillermo-Isidro; Forcén-Muñoz, Luis-Alberto; Ovejero-García, Sanitago; Sáez-Povedano, Rocío; González-Galdámez, Ana-Luisa; Mata-Iturralde, Laura; Ramírez-Bonilla, Mariluz; Fuentes-Pérez, Paloma; Ovejas-Catalán, Claudia; Suárez-Pinilla, Paula; Fernández-Abascal, Blanca; Omana-Colmenares, Miguel; Campos-Navarro, María-Pilar; Baca-García, Enrique; Lara-Fernández, Ana; Benavente-López, Sergio; Raya-Platero, Alberto; Barberán-Navalon, Miguel; Sánchez-Alonso, Sergio; Vázquez-Bourgon, Javier; Pappa, Sofia; García-Carmona, Juan-Antonio
(FRONTIERS MEDIA SA, 2025-03-04)
BACKGROUND: LAIs with longer dosing intervals appear to be associated with improved clinical outcomes and added real-world benefits in the management of schizophrenia. Paliperidone palmitate six-monthly (PP6M) LAI provides ...